Accumulating evidence attests to an important role of T cell–mediated adaptive immunity in regulating tumor evolution, and immunotherapy has emerged as a promising strategy to treat various cancers.
1,2 In colorectal carcinoma, high-level infiltrates of CD3
+, CD8
+, CD45RO (protein tyrosine phosphatase receptor type C [PTPRC])
+, and forkhead box P3 (FOXP3)
+ T cells have been associated with better clinical outcome.
3-6 Evidence also indicates that molecular features of colorectal carcinoma, especially microsatellite instability (MSI), can influence antitumor T cell–mediated adaptive immunity.
7-11